BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Anlotinib Hydrochloride: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04344158 A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma (HCC)active not recruiting648

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05913089 A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerNon Small Cell Lung Cancerrecruiting58

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.